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Abstract
Background: Colorectal cancer (CRC) is often diagnosed at a late stage with concomitant poor prognosis. The
hypersensitive analytical technique of proteomics can detect molecular changes before the tumor is palpable. The
surface-enhanced laser desorption/ionization-time of flight-mass spectra (SELDI-TOF-MS) is a newly-developed
technique of evaluating protein separation in recent years. The protein chips have established the expression of
tumor protein in the serum specimens and become the newly discovered markers for tumor diagnosis. The
objective of this study was to find new markers of the diagnosis among groups of CRC, colorectal benign diseases
(CBD) and healthy controls. The assay of SELDI-TOF-MS with analytical technique of protein-chip bioinformatics was
used to detect the expression of protein mass peaks in the sera of patients or controls. One hundred serum
samples, including 52 cases of colorectal cancer, 27 cases of colorectal benign disease, and 21 cases of healthy
controls, were examined by SELDI-TOF-MS with WCX2 protein-chips.
Results: The diagnostic models (I, II and III) were setup by analyzed the data and sieved markers using Ciphergen -
Protein-Chip-Software 5.1. These models were combined with 3 protein mass peaks to discriminate CRC, CBD, and
healthy controls. The accuracy, the sensitivity and the particularity of cross verification of these models are all
highly over 80%.
Conclusions: The SELDI-TOF-MS is a useful tool to help diagnose colorectal cancer, especially during the early
stage. However, identification of the significantly differentiated proteins needs further study.
Background
Colon cancer is one of the most common cancers and
the fourth leading death in the malignant tumors in the
world. It is reported that approximately 106,100 new
cases of cancer would be diagnosed, and more than
49,920 people would die from cancer in the United
States alone in 2009 [1]. The occurrence of colorectal
cancer was regarded as a multigenic disease according
to modern molecular biology, and genetic abnormality
plays a critical role in the development and progression
of cancer cells [2,3]. By now, except for chemopreven-
tion, there are no certain ways proven to be benefited
for preventing colon cancer. There is an urgent need for
methods to predict and diagnose the patients in the
early stage of colorectal cancer. Therefore, looking for
new techniques with validly, highly and powerful sensi-
tivity are very important for the prevention, prognosis,
and treatment of colorectal cancer. The proteomics have
very important contribution to the cancer diagnosis
based on valuable information of the pathologic physiol-
ogy of the tumor as well as finding new antitumor drugs
[4]. The proteomic pattern would facilitate the early
detection and the development of tumor biomarkers as
well as therapeutic efficacy anticancer drugs [5].
The multichannel detection capability of mass spectro-
metry (MS) enables the position sensitive analysis of
hundreds of different molecules in a single experiment.
MS is increasingly used to profile the serum peptidome
[6]. Magnetic bead-assisted serum peptide capture
coupled to matrix assisted laser desorption/ionization
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trophoresis-based proteomic technology, is a serum pep-
tide profiling strategy gaining in popularity compared to
surface-enhanced laser desorption/ionization (SELDI) -
based platforms due to superior resolution of MALDI
instruments. The MALDI-TOF-MS is also a possibility
to obtain structural (MS/MS) information of signature
peptides and superior binding capacity of the magnetic
beads compared to a flat SELDI-chip surface [7]. It has
been shown to be useful in the discovery of potential
diagnostic markers for cancers such as prostate [8],
ovarian [9], hepatic [10], and breast cancer [11]. In a
previous study, the urine proteome as the early detec-
tion of colorectal cancer from colorectal cancer patients
w a se x a m i n e db yaS E L D Im e t h o d[ 1 2 ] .I na n o t h e r
study, the serum proteome from patients of colorectal
cancer, benign colorectal diseases and healthy volunteers
was also detected by SELDI-TOF-MS. The four proteins
were regarded as effective biomarkers for diagnostics
and therapeutic strategies or monitoring micrometasta-
sis [13]. Thus, this system is a novel, extremely sensitive,
and rapid method to analyze complex mixtures of pro-
teins and peptides. The objective of the present study
was to determine whether comprehensive proteomic
profiling of serum coupled with bioinformatic analysis
methods originally designed for gene expression data
could identify a proteomic printing for effectively differ-
entiating colorectal cancer or benign disease patients.
Methods
Patient and Control Sources
One hundred patients or controls were chosen from the
Affiliated Tumor Hospital of Harbin Medical University,
P. R. China between February and July 2004. There
were 52 cases with colorectal carcinoma (CRC) (28
males and 24 females) from 30 to 80 years old (average
58.9 ± 13.4) and 27 cases (from 43 to 69 and average
55.1 ± 8.6 years old) with colorectal benign disease
(CBD) which were pathologically diagnosed after surgery
(11 males and 17 females) from clinic diagnosis. All
patients did not receive any therapy before blood collec-
tion. All patients with CRC were separated to I, II and
III stages according Dukes’ standards and these cases
did not have distant metastasis. Twenty-one healthy
volunteers (11 males and 10 females) as healthy controls
from 30 to 71 years old (average 47.2 ± 5.8) were
selected from the staffs who were working at clinic. All
patients and healthy controls thoroughly agreed with
and signed the agreements consent for the investigation
in accordance with the ethical guidelines of Harbin
Medical School Ethical Committee. The sera from
patients or healthy controls were distributed into
500 μL aliquots and stored frozen at -80°C for serum
proteomic analysis.
Reagent and Instrument
Experiments were performed using SELDI-TOF-MS
instrument, chip WCX2, and the corresponding analy-
tical software of Ciphergen-Protein-Chipsoftware
5 . 1( C i p h e r g e nB i o s y s t e m sI n c ,F r e m o n t ,C A ) .T h e
reagents such as acetonitrile (HPLC grade), trifluoroa-
cetic acid (TFA), sodium acetate (250 g), SPA ground
substance, CHAPS, TRIS-HCL, DL-dithiothreitol
( D T T )a n du r e a ,w e r eb o u g h tf r o mt h eS i g m a - A l d r i c h
Company (St. Louis, MO).
Sample Preparation
The serum samples from the experimental or control
group were centrifuged at 10,000 rpm for 5 min at 4°C.
Ten μL of the serum sample was filled with 20 μLo f
9 U balanced solutions (9 mol/L Ureas, 2% CHAPSs,
50 mmol/L Tris-HCL, pH 9.0, and 1% DTTs) into the
bores with shaking. The samples were shaking with ice
bath (MS1 Minishaker) at a rate of 400 - 600 rpm for
30 min and then added 360 μL of natrium aceticum
buffer (50 mmol/L NaAc, pH 4.0) with shaking.
Pretreatment, Application of Sample, and Elution
The WCX2 chip (Ciphergen Biosystems Inc, Fremont,
CA) was used throughout this study because this chip
could distinguish the weak differential peaks. The
WCX2 chip placed into the bio-processor was filled
each bore with 200 μL of natrium acetic buffer and
spun the bio-processor at a rate of 400-600 rpm for 5
min and then the buffer was removed. The same pro-
cess mentioned above was repeated again. Each bore of
the bio-processor was filled with 100 μL of the sample,
agitated at a rate of 400-600 rpm for 1 h at 4°C (ice
bath). After removing the sample, 200 μL sodium acet-
ate buffer (50 mmol/L NaAc, pH 4.0 or the binding buf-
fer in kit) was added to each bore, and was spun at a
rate of 400 - 600 rpm for 5 min at room temperature.
This process was also repeated again. Subsequently,
200 μL of HPLC flow phase was added to each bore,
and then discarded immediately. This procedure was
repeated twice. The chip was taken out and added
0.5 μL of SPA solution (50% CANs + 0.5% TFAs) to
each well after exsiccation. After sample exsiccation,
SPA was added again. The samples were dried and ana-
lyzed by the SELDI-TOF-MS system.
Chip Examination, Data Acquisition and Parameter
Enactment
Chips were placed in the SELDI-TOF-MS system
(Ciphergen Biosystems Inc, Fremont, CA), and time-of-
flight spectra were generated by averaging 192 laser shots
collected in the positive mode at laser intensity 215,
detector sensitivity 7. The mass range from molecular
weight 10,000 - 20,000 Da or the highest 50,000 Da was
Liu et al. Proteome Science 2010, 8:16
http://www.proteomesci.com/content/8/1/16
Page 2 of 6selected for analysis because this range contained the
majority of the resolved protein/peptides. The range of
data collection was designed from 10,000 to 50,000 m/z
(mass-to-charge).
Statistical analysis
T h ed a t aw e r ea n a l y z e db ys o f t w a r eo fC i p h e r g e n - P r o -
tein-Chip-software 5.1. When the differentiated expres-
sions of protein mass peak were found among the
groups of colorectal cancer, colorectal benign disease
and healthy controls, these data in the Excel format
were imported into the software of Ciphergen-Protein-
Chip-software 5.1. The significantly different expression
of protein mass peaks (P < 0.05) was listed by the soft-
ware. Subsequently, the differentiated expressions of
protein mass peak were analyzed by discriminatory ana-
l y s i s .T h eb e s ta l i g n m e n tc o m b i n a t i o nw a sa n a l y z e db y
Biomarker Wizard 3.1. Each serum sample was per-
formed at least in triplicate to confirm reproducibility
and reduce bias.
Results
The protein mass peaks (m/z)w e r es i e v e dw i t ht h es / n
exceeding 2 or 5. More than 10% of m/z was sieved in
simultaneous samples with the discrepancy of identical
spinnacle in different samples lower than 0.3% after
removing the noise of initial data. One hundred and
eight-five significant protein mass peaks were found
from 2000 to 20,000 peaks of m/z between the colorec-
tal cancer and control groups, 139 protein mass peaks
between the CRC and CBD groups and 139 protein
mass peaks between the CBD and healthy control
groups.
After discriminatory analysis, 3 of 185 protein mass
peaks were chosen by optimization to establish the com-
bined diagnostic model I (Table 1 and Figure 1), the
categorizing decision tree was built up, and 4 final cru-
nodes were determined (Figure 2). As shown in Table 1,
three protein mass peaks were 12,087.4, 22,603.2, and
13,021.5 m/z (Table 1). The accuracy of diagnostic
model I was 87.67% (64/73), with a sensitivity of 86.54%
(45/52) and specificity of 90.48% (19/21); and the accu-
racy of crossing verification was 82.19% (60/73), with
the sensitivity of 80.77% (42/52) and specificity of
85.71% (18/21).
Three of one hundred and thirty nine protein mass
peaks between the CRC and CBD groups were also cho-
sen by optimization to setup the combined diagnostic
model II (Table 2 and Figure 1), build up the categoriz-
ing decision tree and get 4 final crunodes (Figure 3).
Three protein mass peaks (17,572.8, 15,573, and
18,017.3 m/z) are shown in Table 2. The accuracy of
diagnostic model II was 88.61% (70/79), with the sensi-
tivity of 86.54% (45/52) and the specificity of 92.59%
(25/27), and the accuracy of crossing verification was
87.34% (69/79), with the sensitivity of 86.54% (45/52)
and the specificity of 88.89% (24/27).
Another 139 significant protein mass peaks expressed
differently were analyzed between the CBD and healthy
control groups. The protein mass peaks of 15,361,
17,389.7, and 14,501.8 m/z were chosen by optimization
(Table 3). The combined diagnostic model III was also
setup. The accuracy of this model was 97.92% (47/48),
with the sensitivity of 100% (27/27) and the specificity
of 95.24% (20/21), and the accuracy of crossing verifica-
tion was 91.67% (44/48), with the sensitivity of 92.59%
(25/27) and specificity of 90.48% (19/21).
Discussion
The hypersensitive analytical technique of proteomics
can detect molecular changes before the tumor is palp-
able. This technique has an important role in the diag-
nosis and monitoring of tumors. SELDI-TOF-MS is a
newly-developed technique of evaluating protein separa-
tion in recent years. The protein chips have established
the expression of tumor protein in the serum specimens
including breast, prostate, and bladder cancer. Some of
the proteins from chips have become the newly discov-
ered markers for tumor diagnosis, with higher sensitivity
and specificity than the former markers [8,14-18]. There
are many noninvasive diagnostic methods of colorectal
cancer such as the serum tumor markers (CEA, TPA,
and CA199, etc.), the fecal occult blood test, biochemis-
try, and immunologic test. However, there are high rates
of false positives and false negatives. The sensitivity and
specificity of serum tumor markers still go back and
forth from 50 to 70% [19].
In a previous study [12], the assays of MALDI and
SELDI were used to detect the samples of urine from 67
patients with CRC and 72 non-cancer controls. The
intensities of 19 peaks that differed significantly between
cancer and non-cancer patients were found by multiple
linear regressions. Logistic regression classifiers based
on peak intensities identified CRC with up to 78% sensi-
tivity at 87% specificity. Zheng, et al. [13] reported that
the serum proteome from 63 patients with colorectal
cancer, 20 patients with CBD and 26 healthy volunteers
was also determined by a SELDI-TOF-MS assay. The
two peaks (2753.8 and 4172.4 m/z) detected in that
Table 1 The comparison of 3 protein mass peaks
between the colorectal cancer (CRC) and healthy controls
(HC) groups (mean ± S.D.)
Protein mass-peak(m/z) The CRC The HC P
12087.4 0.044 ± 0.063 0.080 ± 0.045 0.005
22603.2 0.292 ± 0.207 0.182 ± 0.104 0.010
13021.5 0.032 ± 0.021 0.019 ± 0.011 0.022
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Page 3 of 6Figure 1 Protein profiling on WCX2 chips. Representative overview of protein profiling on WCX2 chips showing spectral map (left panel) and
gel view (right panel) of the serum samples. SELDI analysis of human serum for proteomic pattern in the colorectal benign disease (T), healthy
control (N) and colorectal cancer (C) samples with mass spectra (left) and gel view (right). Differentially expressed proteins were found in m/z
values of (A) 15361 Da, (B) 15573 Da and (C) 22603 Da.
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therapeutic strategies in colorectal cancer and the two
proteins (9184.4 and 9340.9 m/z) were effective biomar-
kers for monitoring micrometastasis. In another study
[20], three serum proteins of diagnostic potential (com-
plement C3a des-arg, a1-antitrypsin and transferring)
were identified by SELDI from 62 CRC patients and 31
noncancer subjects. In our study, three serum protein
mass peaks (12,087.4, 22,603.2, and 13,021.5 m/z) from
185 significantly different protein mass peaks between
CRC and control groups were found and established the
combined diagnostic model I. The accuracy of this
model was 87.67%, with a sensitivity of 86.54% and spe-
cificity of 90.48%. Simultaneously, the combined diag-
nostic models II, III were also setup based on 3 serum
protein mass peaks among the CRC, benign disease and
healthy control groups. However, these differentiated
proteins are needed to identify using the assays of syn-
thetic stable isotope peptides or ELISA and to further
confirm these combined diagnostic models using the
patients with CRC. We also need to increase the cases
of early stage of CRC in the analysis, in order to
increase the sensitivity and specificity of combined diag-
nostic models.
The SELDI-TOF-MS and protein chip technique
could discriminate between patients with and without
tumors. However, there are limitations in SELDI-TOF
MS whole serum proteomic profiling with IMAC surface
to specifically detecting colorectal cancer [21]. Wang,
et al. [21] generated a classifier consisting of two serum
protein mass peaks (3961 and 5200 m/z)t h a td i s t i n -
guished 154 patients with CRC from 67 non-cancerous
controls, with promising diagnosis efficiency. But these
two peaks were not CRC-specific; they could not sepa-
rate CRC from other cancer types in the case of patients
who had two or more types of cancers. Thus, whether
we need increase protein mass peaks (least 3) and add
the known markers in the combined diagnostic models,
these efforts are underway in ongoing studies.
Conclusion
In summary, our study indicates that the SELDI-TOF-
MS technique has instructional contributions to diagno-
sis of colorectal cancer, especially in early diagnosis, pre-
operative treatment, staging and prognosis. Our findings
have potential contribution of extensive survey-aided
detection in time among the high-risk patients with CBD.
However, significantly differentiated proteins need to be
identified. A further study is needed to improve the sen-
sitivity and specificity of combined diagnostic models.
Figure 2 Discrimination decision tree models of serum protein
mass-spectrum between the CDR and the healthy controls. The
“n” is the number of samples; the node is a final node.
Table 2 The comparison of 3 protein mass peaks
between the colorectal cancer (CRC) and colorectal
benign disease (CBD) groups (mean ± S.D.)
Protein mass-peak(m/z) The CRC The CBD P
17572.8 0.060 ± 0.043 0.055 ± 0.029 0.003
15573.0 0.027 ± 0.029 0.015 ± 0.010 0.059
18017.3 0.035 ± 0.053 0.053 ± 0.044 0.010
Figure 3 Discrimination decision tree models of serum protein
mass-spectrum between the CRC and CBD groups. “n” is the
number of the samples, and the node is the final node.
Table 3 The comparison of 3 protein mass peaks
between the groups of colorectal benign disease (CBD)
and healthy controls (HC) (mean ± S.D.)
Protein mass-peak(m/z) The CBD The HC P
15361.0 0.810 ± 0.799 0.479 ± 0.346 0.005
17389.7 0.045 ± 0.030 0.022 ± 0.024 0.009
14501.8 0.192 ± 0.083 0.138 ± 0.068 0.046
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